MRES ANNOUNCES RESUMPTION OF THE BUYOUT OFFER AT $0.15 FROM AURIC

Mar 30, 2011, 08:30 ET from Neuro-Biotech Corp.

KAZAN, Russian Federation, March 30 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEETS: MRES) MRES is pleased to announce the resumption of the buyout offer at $0.15 by AURIC Pharma Science.

Following a letter received over the weekend by AURIC, Neuro-Biotech management has decided that it was in both the Company's and shareholders best interest to proceed with the buyout offer. Therefore, the Company would like to announce the completion of its due diligence process and that it will proceed to the closing session of this transaction by Tuesday April 5, 2011. The Company will be announcing the exact time and place of the closing session on Thursday March 31, 2011. Shareholders that would like to participate are invited to register with the Company at: contact@neuro-biotechcorp.com.

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.